A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 376 participants.

Also called NCT07816185

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 376 participants (planned count) (from the registry)
Sponsor
Pulmovant, Inc. (from the registry)
Registry
  • NCT NCT07816185
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07816185. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-31 (actual); primary completion 2029-01-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
Condition
Interstitial Lung Disease
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Fibrosis
Intervention (Drug)
Mosliciguat
Intervention (Drug)
Placebo
Intervention (Device)
Dry Powder Inhaler
Lead sponsor
Pulmovant, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07816185
Content hash
748a2d4da7b92567964d24dbda16029a40f1579b4d5078a242304a8c7d8f8756